Sun Pharma response to import ban inadequate - FDA

Tue May 20, 2014 10:22pm IST

A logo of Sun Pharmaceutical Industries Ltd at its research and development center in Mumbai April 7, 2014.  REUTERS/Danish Siddiqui/Files

A logo of Sun Pharmaceutical Industries Ltd at its research and development center in Mumbai April 7, 2014.

Credit: Reuters/Danish Siddiqui/Files

Related Topics

Stocks

   

REUTERS - Generic drugmaker Sun Pharmaceutical Industries Ltd's (SUN.NS) response to an import ban on one of its plants lacked "sufficient corrective actions," the U.S. Food and Drug Administration said in a warning letter published on Tuesday.

The FDA banned imports from Sun Pharma's Karkhadi plant in Gujarat in March, but the reason for the ban was not clear at that time.

In the warning letter dated May 7 and posted on the FDA website on Tuesday, the regulator said Sun Pharma failed to ensure laboratory records had complete data and that manufacturing staff had inadequate training and experience.

"Your firm frequently performs 'unofficial testing' of samples, disregards the results, and reports results from additional tests," the FDA said in the letter addressed to Sun Pharma CEO Subramanian Kalyanasundaram. (link.reuters.com/pyx49v)

A Sun Pharma spokesman told Reuters on Tuesday that the warning letter shows that the U.S. FDA does not agree with the company's response.

The Karkhadi plant, which makes the antibiotic cephalosporin, is one of Sun Pharma's 25 manufacturing plants.

Sun Pharma, which is planning to buy its struggling rival Ranbaxy Laboratories Ltd (RANB.NS) for $3.2 billion, had said in March that the import ban would have negligible financial impact.

The FDA has unleashed a wave of restrictions, warnings and bans on Indian generic drug firms over the past one year, citing serious manufacturing and quality control problems.

(Reporting by Esha Dey in Bangalore and Zeba Siddiqui in Mumbai; Editing by Sriraj Kalluvila)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Culling Plans

REUTERS SHOWCASE

Root Out 'Bad Apples'

Root Out 'Bad Apples'

RBI chief calls for cleaning up of banking system.  Full Article 

Android One

Android One

Google launches $105 Android One; eyes low-price smartphone boom.  Full Article 

India-Vietnam Ties

India-Vietnam Ties

India tightens Vietnam defence, oil ties ahead of China Xi's visit.  Full Article 

Cognizant Deal

Cognizant Deal

Cognizant to buy TriZetto for $2.7 billion to boost healthcare business  Full Article 

Inflation Eases

Inflation Eases

Aug WPI inflation eases to near five-year low of 3.74 percent  Full Article 

Kashmir Floods

Kashmir Floods

Disease threatens as Kashmir flood waters turn fetid  Full Article 

Hepatitis Drug

Hepatitis Drug

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others   Full Article 

Trade Deficit

Trade Deficit

Exports growth slows to 2.4 pct in August  Full Article 

Battle for Heineken

Battle for Heineken

Four generations on, Heineken family won't loosen grip  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage